Back to All Combinations
STK11/LKB1 Loss
Intermediate PrognosisGenes Involved
STK11
Treatment Implications
May cause immunotherapy resistance. Watch for CRC data.
Recommended Treatments
Standard therapy
Metabolic targeting trials
Treatments to Avoid
No specific contraindications noted
Study References
Lung cancer data
Key Statistics
2.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Better understood in lung cancer.
Information
Category: Emerging Targets
Evidence Level: Level 3
Last Updated: Dec 7, 2025
Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.